Synkrino Biotherapeutics
Synkrino Biotherapeutics, based in Oakland, CA, specializes in AI-driven drug discovery and delivery within the healthcare sector, serving regions across the USA and Canada.
Company History
Synkrino Biotherapeutics, formerly known as SF17 Therapeutics, is based in Oakland, CA, USA. The company participated in Y Combinator's S18 batch. Since its inception, Synkrino Biotherapeutics has been dedicated to advancing healthcare through innovative drug discovery and delivery methods.
Services
Synkrino Biotherapeutics offers advanced drug discovery and delivery services within the healthcare sub-industry. They utilize artificial intelligence, particularly their proprietary AI system SATIS, to drive their research and development efforts. The company is currently in the early stages but is making significant strides in healthcare innovation.
Location and Regions Served
Synkrino Biotherapeutics is headquartered in Oakland, CA, USA. The company primarily serves regions within the United States and extends its services to America and Canada. This strategic location allows them to tap into key markets in North America, crucial for their early-stage growth and development.
Team and Industry Focus
Operating with a small team of 2, Synkrino Biotherapeutics is focused on the healthcare industry, particularly in the niche of drug discovery and delivery. Leveraging their specialized knowledge and cutting-edge technology, the team aims to make impactful contributions to healthcare.